Skip to content
value.today

Aset Therapeutics, Inc.

🇺🇸 Stony Brook, New York, USABiotechnologyFounded 2016
Total raised
$146 M
4 rounds on record
Latest round
$85 M
Nov 2019
First round on record
Mar 2017
Today
Went public
See the company page

Aset Therapeutics, Inc. is listed today as Black Diamond Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aset Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2019$85 MNo. 4$50 to $250 million

Aset Therapeutics, Inc.: Raise no. 4, Nov 2019

Investors in this round

28 investors had bought by the notice of Dec 6, 2019: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Aset Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $85 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent M. Hatzis-Schoch · Executive Officer
  • Christopher M. Roberts · Executive Officer
  • David M. Epstein · Executive Officer, Director
  • Thomas M. Leggett · Executive Officer
  • Alexander M. Mayweg · Director
  • Ali M. Behbahani · Director
  • Bradley M. Bolzon · Director
  • Garry M. Menzel · Director
  • Rajeev M. Shah · Director
  • Samarth M. Kulkarni · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Epstein, President & CEO. Source: SEC Form D, newest notice filed Dec 6, 2019. Read the notice at the SEC.

equitySEC
Dec 2018$44 MNo. 3$10 to $50 million

Aset Therapeutics, Inc.: Raise no. 3, Dec 2018

Investors in this round

16 investors had bought by the notice of Jul 16, 2019: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Aset Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$44 M of $87 M offered; $43 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent E. Hatzis-Schoch · Executive Officer
  • David M. Epstein · Executive Officer, Director
  • Elizabeth M. Buck · Executive Officer
  • Fang M. Ni · Executive Officer
  • Alexander M. Mayweg · Director
  • Ali M. Behbahani · Director
  • Bradley M. Bolzon · Director
  • Garry E. Menzel · Director
  • Rajeev M. Shah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Epstein, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 16, 2019. Read the notice at the SEC.

equitySEC
Aug 2018$5 MNo. 2$2 to $10 million

Aset Therapeutics, Inc.: Raise no. 2, Aug 2018

Investors in this round

1 investor had bought by the notice of Aug 22, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Aset Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Epstein · Executive Officer, Director
  • Elizabeth E. Buck · Executive Officer
  • Alexander M. Mayweg · Director
  • Bradley M. Bolzon · Director
  • Garry E. Menzel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Epstein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 22, 2018. Read the notice at the SEC.

equitySEC
Mar 2017$12 MNo. 1$10 to $50 million

Aset Therapeutics, Inc.: Raise no. 1, Mar 2017

Investors in this round

11 investors had bought by the notice of Jan 4, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Aset Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M Epstein · Executive Officer, Director
  • Elizabeth M Buck · Executive Officer
  • Alexander M Mayweg · Director
  • Brad E Bolzon · Director
  • Garry E Menzel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Epstein, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 4, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Black Diamond Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Reportable segment $70 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Aset Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2019).

    SEC Form D · Dec 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2019

Products and services#

No products or services of Aset Therapeutics, Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in Aset Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
David M. EpsteinPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2020)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Deerfield Partners, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Nea 16 GP, LLCOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
NEA Partners 16, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
New Enterprise Associates 16, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Versant Vantage I, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Versant Venture Capital VI, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Versant Voyageurs I, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Versant Voyageurs I Parallel, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 28 investors.

Largest shareholders today

Institutions holding Black Diamond Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aset Therapeutics, Inc.
NameRoleNamed in
Brent M. Hatzis-SchochExecutive officerDec 2019
Christopher M. RobertsExecutive officerDec 2019
David M. EpsteinExecutive officerDec 2019
Thomas M. LeggettExecutive officerDec 2019
Brent E. Hatzis-SchochExecutive officerJul 2019
Elizabeth M. BuckExecutive officerJul 2019
Fang M. NiExecutive officerJul 2019
Elizabeth E. BuckExecutive officerAug 2018
David M EpsteinExecutive officerJan 2018
Elizabeth M BuckExecutive officerJan 2018
Alexander M. MaywegDirectorDec 2019
Ali M. BehbahaniDirectorDec 2019
Bradley M. BolzonDirectorDec 2019
David M. EpsteinDirectorDec 2019
Garry M. MenzelDirectorDec 2019
Rajeev M. ShahDirectorDec 2019
Samarth M. KulkarniDirectorDec 2019
Garry E. MenzelDirectorJul 2019
Alexander M MaywegDirectorJan 2018
Brad E BolzonDirectorJan 2018
David M EpsteinDirectorJan 2018
Garry E MenzelDirectorJan 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.